Selection of a lead candidate for the development of a novel anti-inflammatory therapeutic
Ended Project Grant Awarded Last action
- Award ID
- R43AI155239
- Recipient
-
Peel Therapeutics Inc. UEI G1X8J9LJZM78
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $899,024
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Funding
-
- $599,349.30 Federal
- $299,675.00 Non-federal
- Place of performance
- Salt Lake City, UT 84112, USA
Award details come from USAspending.gov.
Description
- Abstract
- Peel therapeutics, INC. (peel) is pioneering a novel approach to prevent morbidity and mortality associated with inflammatory disease through the inhibition of neutrophil extracellular traps (nets). Nets are lattices of decondensed chromatin decorated with histones and antimicrobial proteins extruded by polymorphonuclear leukocytes (pmns) to trap and kill microbes. While regulated net formation contains infection, dysregulated net formation leads to inflammatory tissue damage and vascular injury. Nets have been implicated in human diseases characterized by inflammation, including sepsis, stroke, diabetes, and heart disease. The ability of net- inhibitory factors (nifs) to block PMN-dependent net formation makes this newly described class of endogenous peptides a promising therapeutic modality for diseases caused and/or exacerbated by net-dependent inflammatory events. In this phase i sbir, peel will quantify and compare the biological activity and pharmacokinetics of two nifs in vitro and in vivo. The lead NIF peptide will move forward in the development of a novel anti-net therapeutic. After completing these sbir phase i tasks, peel therapeutics will be in an excellent position to advance its new and patented NIF-based therapeutic to further preclinical studies. These efforts by peel therapeutics hold the potential to disrupt and improve the treatment approach to both acute and chronic inflammatory diseases.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$1 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $299,675 | $0 | |
| Original award | $299,675 | $299,675 |
Quick answers
Who received award R43AI155239?
R43AI155239 was awarded to Peel Therapeutics Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on April 15, 2021.
How much is award R43AI155239 worth?
$899,024 has been obligated on R43AI155239: $599,349 in federal funding and $299,675 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award